

## Gabapentin effectiveness on the sensation of subjective idiopathic tinnitus: A pilot study

Bakhshaei, M.<sup>a</sup>, Ghasemi, M.<sup>b</sup>, Azarpazhooh, M.<sup>c</sup>, Khadivi, E.<sup>a</sup>, Rezaei, S.<sup>a</sup>, Shakeri, M.<sup>d</sup>, Tale, M.<sup>e</sup>

<sup>a</sup> Otorhinolaryngology-Head and Neck Surgery Department, Imam Reza Educational Hospital, **Mashhad University of Medical Sciences, Mashhad**, Iran

<sup>b</sup> Otorhinolaryngology-Head and Neck Surgery Department, Qaem Educational Hospital, **Mashhad University of Medical Sciences, Mashhad**, Iran

<sup>c</sup> Neurology Department, Qaem Educational Hospital, **Mashhad University of Medical Sciences, Mashhad**, Iran

<sup>d</sup> Department of Community Medicine, Qaem Educational Hospital, **Mashhad University of Medical Sciences, Mashhad**, Iran

<sup>e</sup> Cochlear Implant Center, **Mashhad**, Iran

[View references \(^ ^\)](#)

### Abstract

This prospective, placebo-controlled, double-blind clinical trial evaluated the effectiveness of gabapentin in decreasing subjective features of idiopathic subjective tinnitus in the patients. Pure-tone audiograms, laboratory test and personal histories were used to exclude any particular etiology of tinnitus. Participants were restricted to those with moderate to severe idiopathic subjective tinnitus for at least 6 months. A total of 20 participants received gabapentin in a graduated ascending dose series extending over 4 weeks (peak dose of 900 mg/day). There was not a significant subjective improvement in tinnitus annoyance for the patients (37%) versus controls (42%). Comparison between the results before and after intervention for patients and controls according to subjective response, tinnitus questionnaire, tinnitus severity index and the loudness perception by the patients showed no significant differences ( $P > 0.05$ ). There is insufficient evidence to support the effectiveness of gabapentin in the treatment of tinnitus up to now. © 2017 Springer-Verlag.

### Reaxys Database Information

#### Author keywords

Gabapentin; Tinnitus; Treatment

#### Indexed Keywords

**EMTREE drug terms:** gabapentin

**EMTREE medical terms:** adult; aged; article; clinical article; clinical trial; controlled clinical trial; controlled study; disease severity; dizziness; double blind procedure; drug dose escalation; drug efficacy; drug withdrawal; female; human; idiopathic disease; laboratory test; loudness; male; priority journal; prospective study; pure tone audiometry; questionnaire; sensation; statistical significance; tinnitus; treatment duration

**MeSH:** Adult; Aged; Aged, 18 and over; Amines; Cyclohexanecarboxylic Acids; Double-Blind Method; Excitatory Amino Acid Antagonists; Female; gamma-Aminobutyric Acid; Humans; Male; Middle Aged; Pilot Projects; Tinnitus; Treatment Failure

*Medline is the source for the MeSH terms of this document.*

**Chemicals and CAS Registry Numbers:** gabapentin, 70142-96-3; Amines; Cyclohexanecarboxylic Acids; Excitatory Amino Acid Antagonists; gabapentin, 70142-96-3; gamma-Aminobutyric Acid, 56-12-2

**Drug tradename:** neurontin, Pfizer.

**Manufacturers:Drug manufacturer:** Pfizer.